Skip to search formSkip to main content
You are currently offline. Some features of the site may not work correctly.

SY0916

 
National Institutes of Health

Papers overview

Semantic Scholar uses AI to extract papers important to this topic.
2019
2019
SY0916 has been proven to be a potent treatment agent against rheumatoid arthritis in preclinical studies and has been shown to… Expand
  • figure 1
  • figure 2
  • figure 3
  • figure 4
  • table 1
Is this relevant?
2016
2016
Pain greatly affects the quality of life of people worldwide. Despite their demonstrated efficacy, currently used opioid drugs… Expand
Is this relevant?
2014
2014
SY0916 is a new platelet-activating factor receptor antagonist developed by our institute. In this study, the inhibitory effect… Expand
Is this relevant?
2011
2011
SY0916 is a novel platelet-activating factor receptor antagonist. The objective of this study is to explore the anti-angiogenesis… Expand
Is this relevant?
2011
2011
OBJECTIVE To investigate the in vitro anti-angiogenesis effect of platelet activating factor(PAF)receptor antagonist SY0916 on… Expand
Is this relevant?
2010
2010
AbstractAim:To study the effects and mechanism of aromatic aminoketone (SY0916) on bone destruction in vitro.Methods:MC3T3-E1… Expand
  • figure 1
  • table 1
  • figure 2
  • table 2
  • figure 3
Is this relevant?